ALF-ONE : ALFuzosin ONcE Daily

Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China

The aim of the study is to collect, under daily practice conditions, clinical data on the safety profile and the efficacy of a new formulation of alfuzosin administered once daily in patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).

Inclusion Criteria:

• Ambulatory patients suffering from Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia

Exclusion Criteria:

• Patients requiring Benign Prostatic Hyperplasia surgery immediately or within the 12 following months
• Patients previously not improved by an alpha 1-blocker treatment
• Patients whose urinary symptoms are satisfactorily controlled on other Benign Prostatic Hyperplasia medication (alpha 1-blockers and 5-ARI)
• Known hypersensitivity to alfuzosin
• History of postural hypotension or syncope
• Combination with other alpha 1-blockers
• Hepatic insufficiency
• Unstable angina pectoris
• Severe concomitant condition threatening life